Celgene exec Chris Hugin linked to $280 M settlement and political attacks over Revlimid price hikes

Celgene exec Chris Hugin linked to $280 M settlement and political attacks over Revlimid price hikes The passage identifies a former Celgene executive (Chris Hugin) who was involved in aggressive marketing of Revlimid/Thalomid, a $280 M whistle‑blower settlement, and political targeting by a super‑PAC and Senator Menendez. It provides concrete names, a settlement amount, and a political angle, offering actionable leads (e.g., trace payments, PAC contributions, lobbying disclosures). However, the information is largely already public and lacks new financial transaction details or direct evidence of wrongdoing beyond known settlements, limiting its novelty and impact. Key insights: Chris Hugin was a top executive at Celgene during the Revlimid/Thalomid controversy.; Celgene paid $280 M to settle a whistle‑blower lawsuit alleging off‑label promotion.; A super‑PAC funded by a Revlimid‑using cancer patient ran a $1.5 M ad campaign criticizing drug price hikes during Hugin’s tenure.